Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPINORM is a topical gel formulation developed by Epitech, primarily containing the ALIAmide adelmidrol. It is designed for gynecological applications, specifically to manage chronic pelvic pain, vulvar discomfort, and to promote healing after episiotomy. The mechanism of action involves the ALIA (Autacoid Local Injury Antagonism) effect, where adelmidrol modulates the activation and degranulation of mast cells and other non-neuronal immune cells. By downregulating mast cell hyperactivity, EPINORM helps reduce inflammation and associated pain in the pelvic and vaginal tissues. It is currently approved and marketed in certain regions, particularly in Europe, often classified as a medical device for local application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EPINORM.